0700 GMT - CSPC Pharmaceutical's out-licensing revenue is likely to be a sizeable revenue source for the company in 2025 and going forward, Nomura's Jialin Zhang says in a research report, as the brokerage raises the stock's target price to HK$6.55 from HK$6.48 with an unchanged buy rating. At its 2024 earnings call, management reiterated "positive sales growth" for 2025 due to potentially CNY1.5 billion in additional sales from newly-launched drugs and collaboration revenue, the analyst notes. Management is confident of maintaining the current out-licensing pace in coming years owing to the company's broad early-stage innovative drug portfolio. For central nervous system drugs, management expects positive growth for its 'NBP' products and around CNY1 billion of sales from its Mingfule drug, the analyst adds. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
March 31, 2025 03:00 ET (07:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。